Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378352 · ClinicalTrials.gov registry record · Phase 2
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
A Phase 2 study of Acute ST Elevation Myocardial Infarction, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
- 16
- Study locations
NCT00378352 is a Phase 2 study of Acute ST Elevation Myocardial Infarction that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 223 participants. The trial reports 16 study locations across 11 states.
The verdict
NCT00378352, a Phase 2 study of Acute ST Elevation Myocardial Infarction, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
Conditions Studied
Interventions
- DRUG Epoetin alfa
Study Locations (16)
New York
- New York Methodist Hospital - Brooklyn
- Cornell University - New York
- NY Presbyterian Hospital - New York
- Weill Medical College - New York
Michigan
- Henry Ford Hospital - Detroit
- William Beaumont Hospital - Royal Oak
North Carolina
- Duke University - Durham
- Wake Forest University - Winston-Salem
District of Columbia
- Washington Hospital Center - Washington D.C.
Florida
- University of Miami, School of Medicine - Miami
Georgia
- Emory University Hospital - Atlanta
Minnesota
- Mayo Clinic, Rochester - Rochester
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378352
The ClinicalTrials.gov registry entry for NCT00378352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute ST Elevation Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT00378352 reports 16 study locations spanning 11 distinct geographic areas - top geographies include New York, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00378352 about?
NCT00378352 is a clinical study titled "REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction". The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
What is the current status of trial NCT00378352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2005-09. Estimated completion is 2011-01.
What conditions does trial NCT00378352 study?
This clinical trial studies the following conditions: Acute ST Elevation Myocardial Infarction.
What interventions are being tested in trial NCT00378352?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00378352?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00378352 being conducted?
This trial has 16 study locations across District of Columbia, Florida, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.